CONSULTING AND OTHER AGREEMENTS	9 Months Ended
Sep. 30, 2025
Consulting And Other Agreements
CONSULTING AND OTHER AGREEMENTS	11. CONSULTING AND OTHER AGREEMENTS The following agreements were entered into or remained in force during the periods ended September 30, 2025 and 2024: On August 27, 2024 Vycor entered into a financial advisory and investment banking services agreement (“Agreement”) with Maxim. Under the terms of the Agreement, Maxim will assist Vycor in its strategy to grow the Company through strategic acquisitions and assist the Company with efforts to position itself for a potential uplisting to a US exchange. Vycor issued 813,971 shares of Company Common Stock (valued at $73,257) and additional fees would be payable under the agreement subject to the closing of acquisitions or other investment banking transactions. The amortization for the three and nine months ended September 30, 2025 was $12,209 and $48,838 respectively and for the three and nine months ended September 30, 2024 was $6,105 (see Note 8 and Note 9). On March 30, 2021, Vycor entered into a Consulting Agreement with Ricardo J. Komotar, M.D. (the “Agreement”) to provide certain specified services over the three-year term of the Agreement. On April 1, 2023, 101,663 shares of Company Common Stock (valued at $9,455) were issued under the terms of the Agreement, which was amortized over twelve months, with amortization for the three and nine months ended September 30, 2024 of $0 and $2,364 respectively (see Note 9).

CONSULTING AND OTHER AGREEMENTS

9 Months Ended

Sep. 30, 2025

11. CONSULTING AND OTHER AGREEMENTS

The following agreements were entered into or remained in force during the periods ended September 30, 2025 and 2024:

On August 27, 2024 Vycor entered into a financial advisory and investment banking services agreement (“Agreement”) with Maxim. Under the terms of the Agreement, Maxim will assist Vycor in its strategy to grow the Company through strategic acquisitions and assist the Company with efforts to position itself for a potential uplisting to a US exchange. Vycor issued 813,971 shares of Company Common Stock (valued at $73,257) and additional fees would be payable under the agreement subject to the closing of acquisitions or other investment banking transactions. The amortization for the three and nine months ended September 30, 2025 was $12,209 and $48,838 respectively and for the three and nine months ended September 30, 2024 was $6,105 (see Note 8 and Note 9).

On March 30, 2021, Vycor entered into a Consulting Agreement with Ricardo J. Komotar, M.D. (the “Agreement”) to provide certain specified services over the three-year term of the Agreement. On April 1, 2023, 101,663 shares of Company Common Stock (valued at $9,455) were issued under the terms of the Agreement, which was amortized over twelve months, with amortization for the three and nine months ended September 30, 2024 of $0 and $2,364 respectively (see Note 9).

VYCOR MEDICAL INC 10-Q